Evidence map›Paper›PMID 40782806›Full record

ArticleCell chemical biology2025

A method for the detection and enrichment of endogenous cereblon substrates.

Hannah C Lloyd, Yuli Li, N Connor Payne, Zhenguang Zhao, Wenqing Xu, Alena Kroupova, David Zollman, Tengfang Long, Farah Kabir, Mei Chen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Chemical and Enzymatic Approaches to C-Terminal Cyclic Imide Formation.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Hannah C LloydDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Yuli LiDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
N Connor PayneDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
Zhenguang ZhaoDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Wenqing XuDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Alena KroupovaCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee DD1 5JJ, UK.
David ZollmanCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee DD1 5JJ, UK.
Tengfang LongDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Farah KabirDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Mei ChenHarvard Center for Mass Spectrometry, Division of Science, Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA.
Rebecca FreemanDepartment of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Ethan Yang FengDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Sarah Y XiDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Ya-Chieh HsuDepartment of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Alessio CiulliCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee DD1 5JJ, UK.
Ralph MazitschekCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Christina M WooDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: cwoo@chemistry.harvard.edu.

Funding

Uncovering the substrate recognition mechanisms of the E3 ligase adaptor cereblonR01GM141406 · NIGMS · HARVARD UNIVERSITY · PI WOO, CHRISTINA · 2022 to 2025
$1.3M
Defining Sexual Dimorphism in the SkinF31AR083715 · NIAMS · HARVARD MEDICAL SCHOOL · PI FREEMAN, REBECCA JANE · 2024 to 2025
$80k
NIAMS NIH HHS F31 AR083715NIGMS NIH HHS R01 GM141406
6 · The paper itself

Abstract

C-terminal cyclic imides are posttranslational modifications (PTMs) on proteins that are recognized and removed by the E3 ligase substrate adapter cereblon (CRBN). Despite the observation of these modifications across the proteome by mass spectrometry-based proteomics, an orthogonal and generalizable method to visualize the C-terminal cyclic imide would enhance detection, sensitivity, and throughput of endogenous CRBN substrate characterization. Here, we develop an antibody-like reagent, termed "cerebody," for visualizing and enriching C-terminal cyclic imide-modified proteins. We describe the engineering of CRBN derivatives to produce cerebody and use it to identify CRBN substrates by western blot and enrichment from whole-cell and tissue lysates. CRBN substrates identified by cerebody enrichment are mapped, validated, and further characterized for dependence on the C-terminal cyclic imide modification. These methods will accelerate the characterization of endogenous CRBN substrates and their regulation.

Indexed as

Adaptor Proteins, Signal TransducingUbiquitin-Protein LigasesAnimalsHEK293 CellsHumansMiceProtein Processing, Post-TranslationalProteomicsSubstrate SpecificityAdaptor Proteins, Signal TransducingCRBN protein, humanUbiquitin-Protein Ligasescerebloncyclic imidedegronE3 ligaseposttranslational modificationprotein degradationprotein engineering

Identifiers

PMID40782806
PMCPMC12360616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.